| 1/11/2021 |
Needham Believes Thermo Fisher (TMO) Still Has Room to Grow |
markets.co |
... week high of $532.57.According to TipRanks.com , Unger is a 5-star analyst with an average return of 41.6% and a 78.2% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics , PerkinElmer, and NeoGenomics.Currently, the analyst consensus on Thermo Fisher is a Strong Buy with an average price target of $534.08, representing a 4.9% upside. In a report issued on January 8, Credit Suisse ... |
| 1/11/2021 |
Needham Gives a Buy Rating to PerkinElmer (PKI) |
markets.co |
... week high of $162.40.According to TipRanks.com , Unger is a 5-star analyst with an average return of 41.6% and a 78.2% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics , Thermo Fisher, and NeoGenomics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PerkinElmer with a $158.25 average price target, which is a -0.4% downside from current levels ... |
| 1/8/2021 |
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula® |
Globe Newswire |
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice ® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula ® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as ... |
| 1/8/2021 |
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula® |
dailymagazine.news |
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice ® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula ® (niraparib). myChoice was approved by Japan's Ministry of Health, Labour and Welfare in September 2020 as a ... |
| 1/6/2021 |
Cal-Maine Foods, Myriad Genetics & more |
bitcoinethereumnews.com |
Bitcoin Ethereum NewsCases of eggs from Cal-Maine Foods, Inc., await to be handed out by the Mississippi Department of Agriculture and Commerce employees to several hundred families along with over 1,400 boxes of meat products from Merchants Foodservice and 2,200 gallons of milk from Borden Dairy, at the Mississippi State Fairgrounds in Jackson, Miss., Aug. 7, 2020.Rogelio V. Solis APCheck out the companies making headlines after ... |
| 1/6/2021 |
Google Alert - biggest |
blogspot.com |
biggest As-it-happens update ‚ãÖ January 5, 2021 NEWS Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more CNBC Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more. Published Tue, Jan 5 20214:46 PM EST Updated Tue, Jan ... Flag as irrelevant Jeff Bezos tops list of biggest charitable givers in 2020 CBS News According to the left-leaning Americans ... |
| 1/6/2021 |
Cal-Maine Foods, Myriad Genetics & more |
gleeconsultinggroup.com |
GLEE CONSULTING GROUP Business Finance Cal-Maine Foods, Myriad Genetics & more Cal-Maine Foods, Myriad Genetics & more DrGlee Business FinanceCases of eggs from Cal-Maine Foods, Inc., await to be handed out by the Mississippi Department of Agriculture and Commerce employees to several hundred families along with over 1,400 boxes of meat products from Merchants Foodservice and 2,200 gallons of milk from Borden Dairy, at the Mississippi State Fairgrounds ... |
| 1/6/2021 |
Myriad Genetics (NASDAQ:MYGN) Shares Up 8.3% |
Daily Political |
Myriad Genetics (NASDAQ:MYGN) Shares Up 8.3% January 5th, 2021 - Comments Off on Myriad Genetics (NASDAQ:MYGN) Shares Up 8.3% - Filed Under - by Stacy Sanders TweetMyriad Genetics, Inc. (NASDAQ:MYGN) shares shot up 8.3% during mid-day trading on Tuesday . The company traded as high as $21.75 and last traded at $21.58. 686,912 shares traded hands during mid-day trading, a decline of 6% from the average session volume ... |
| 1/6/2021 |
Myriad Decides to Sell Vectra DA, Reorganize International Presence After Strategic Review |
genomeweb.com |
staff reporterNEW YORK – Myriad Genetics said after the close of the market on Tuesday that after completing a strategic review of its business units and products, the company has decided to seek a buyer for its autoimmune business, including rheumatoid arthritis test Vectra DA, and reorganize its international operations. To read the full story.... Email: ...and receive Daily News bulletins. Already have a GenomeWeb or 360Dx account ... |
| 1/6/2021 |
Myriad Genetics (NASDAQ:MYGN) Rating Lowered to Buy at ValuEngine |
The Markets Daily |
Myriad Genetics (NASDAQ:MYGN) Rating Lowered to Buy at ValuEngine Posted by Sarita Garza on Jan 6th, 2021 // Comments offValuEngine downgraded shares of Myriad Genetics (NASDAQ:MYGN) from a strong-buy rating to a buy rating in a research note issued to investors on Tuesday, ValuEngine reports.Other equities analysts have also recently issued reports about the company. BidaskClub raised Myriad Genetics from a hold rating to a buy ... |
| 1/6/2021 |
Myriad Genetics to Sell Vectra DA Business, Reorganize International Presence |
genomeweb.com |
staff reporterNEW YORK – Myriad Genetics said after the close of the market on Tuesday that after completing a strategic review of its business units and products, the company has decided to seek a buyer for its autoimmune business, including rheumatoid arthritis test Vectra DA, and reorganize its international operations. To read the full story.... Email: ...and receive Daily News bulletins. Already have a GenomeWeb or 360Dx account ... |
| 1/5/2021 |
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations |
gurufocus.com |
Focus on Women’s Health, Oncology, Mental Health to Improve Execution and Accelerate Growth SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. ( MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic business unit and products review which will enable the company to better serve patients and healthcare providers and further expand its leadership in Women’s Health, Oncology and ... |
| 1/5/2021 |
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations |
tmcnet.com |
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations [January 05, 2021] Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic business unit and products review which will enable the company ... |
| 1/5/2021 |
Myriad Genetics (NASDAQ:MYGN) Downgraded by ValuEngine |
zolmax.com |
... Äústrong-buy‚Äù rating to a ‚Äúbuy‚Äù rating in a research note issued to investors on Tuesday, ValuEngine reports.Several other research firms have also issued reports on MYGN. BidaskClub raised shares of Myriad Genetics from a ‚Äúhold‚Äù rating to a ‚Äúbuy‚Äù rating in a report on Friday, December 25th. Piper Sandler boosted their target price on Myriad Genetics from $14.00 to $18.00 and gave the stock ... |
| 1/5/2021 |
Myriad Genetics (NASDAQ:MYGN) Cut to “Buy” at ValuEngine |
Daily Political |
... at ValuEngine from a “strong-buy” rating to a “buy” note issued to investors on Tuesday, ValuEngine reports.Several other equities analysts have also recently commented on the stock. BidaskClub raised shares of Myriad Genetics from a “hold” rating to a “buy” report on Friday, December 25th. Piper Sandler lifted their target price on Myriad Genetics from $14.00 to $18.00 and gave the company a “neutral” ... |
| 1/5/2021 |
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more |
CNBC |
span class="HighlightShare-hidden" style="top:0;left:0" /span div class="InlineImage-imageEmbed hasBkg" id="ArticleBody-InlineImage-106819478" data-test="InlineImage" div class="InlineImage-wrapper" div class="InlineImage-imagePlaceholder" style="padding-bottom:56.25%" div div style="height:100%" class="lazyload-placeholder" /div /div /div div div class="InlineImage-imageEmbedCaption" Cases of eggs from Cal-Maine Foods, Inc., await to be handed out by the Mississippi Department of Agriculture and ... |
| 1/5/2021 |
Cal-Maine Foods, Myriad Genetics & more | |
vixc.com |
... 347.3 million. Analysts polled by FactSet expected a loss of 8 cents pre share on revenue of $333.5 million. The company’s egg-dozen sales grew by 4.6% on a year-over-year basis. Myriad Genetics — Shares of the biotechnology company rose nearly 2% on news Myriad will explore “strategic alternatives” for its autoimmune business. The company is also restructuring its international operations. Smart Global Holdings — Smart ... |
| 1/4/2021 |
MYGN: Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference |
blogspot.com |
New alert via PocketInfo for MYGN:Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare ConferencePress Releases: http://investor.myriad.com/releases.cfmSEC Filings: http://investor.myriad.com/sec.cfmStock News Alerts by Pocket Info - the appOur free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screenhttps://itunes.apple.com/sg/app/stock ... |
| 1/4/2021 |
Public Thinker: Shobita Parthasarathy on Why We Need to Diversify Expertise |
publicbooks.org |
... in innovation, this is what we need for innovation, and therefore we need to move forward.DS: Why wasn’t it the job of bioethicists to step outside of that role and say—with Myriad Genetics specifically and patentable genes generally—here is a tension between a moral cost and a commitment to innovation, and we have to openly debate that?SP: In the history of how bioethicists have figured ... |
| 12/31/2020 |
Molecular Diagnostics Equipment MARKET BOOSTING THE GROWTH WORLDWIDE: Molecular Diagnostics Equipment MARKET DYNAMICS AND TRENDS, EFFICIENCIES FORECAST 2029 |
chemicalsnewspaper.com |
... diagnostics-equipment-market/request-sampleScope of the Report:This report focuses on the Molecular Diagnostics Equipment,Roche Diagnostics, QIAGEN N.V., Abbott Laboratories, Hologic Inc., Grifols, Cepheid Inc., Genomic Health, Inc., Sequenom, Luminex Corporation, Myriad Genetics , Inc., Foundation Medicine, Inc., Natera inc.• Molecular Diagnostics Equipment market segmentation:Global molecular diagnostic market segmentation by technology:Polymerase chain reaction (PCR)Isothermal nucleic acid amplification technology (INAAT)Hybridization [in situ hybridization & fluorescent ... |